Articles tagged "Immunosuppression"

2016 American Transplant Congress
Evaluation of Patient-Reported Nonadherence with Tacrolimus Level Variability in Renal Transplant Recipients.
N. Parrish,¹ T. Kaiser,² A. McCann,¹ J. Aladimi,² J. Harris,³ A. Govil,² B. Abu Jawdeh,² G. Mogilishetty,² R. Alloway,² E. Woodle.²
¹Pharmacy Services, University of Cincinnati Medical Center, Cincinnati, OH; ²Medicine, University of Cincinnati, Cincinnati, OH; ³Transplant, University of Cincinnati Medical Center, Cincinnati, OH.
Medication nonadherence (NA) continues to be a major cause of graft loss post-transplant. Several methods for prospective adherence monitoring have been described including patient interview…
2016 American Transplant Congress
Predictive Model for Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, SC.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to create a model to…
2016 American Transplant Congress
Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant.
A. Shetty,¹ T. Opas,¹ J. Mathew,¹ V. Mas,² J. Leventhal,¹ N. Sustento-Reodica,¹ L. Gallon.¹
¹Northwestern University, Feinberg School of Medicine, Chicago, IL; ²University of Virginia, Charlottesville, VA.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…
2016 American Transplant Congress
Increasing Tacrolimus Time-in-Therapeutic Range Is Associated with Less Cellular Rejection in Lung Transplant Recipients.
C. Ensor, K. Harrigan, R. Venkataramanan, M. Morrell, C. Moore, J. Hayanga, M. Crespo, J. DCunha, A. Zeevi, J. McDyer.
University of Pittsburgh, Pittsburgh, PA.
Purpose: To describe the effect of tacrolimus (FK) time-in-therapeutic range (TTR) on incidence of cellular rejection (ACR) within the first year after lung transplantation (LT).Methods:…
2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
X. Wen,¹ M. Casey,¹ A. Santos,¹ A. Hartzema,² K. Womer.¹
¹Department of Medicine, University of Florida, Gainesville, FL; ²Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…
2016 American Transplant Congress
Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.
P. Gatault,¹ N. Kamar,² M. Buchler,¹ C. Colosio,³ D. Bertrand,⁴ A. Durrbach,⁵ L. Albano,⁶ J. Rivalan,⁷ M. Essig,⁸ Y. Le Meur,⁹ N. Bouvier,¹⁰ B. Charpentier,⁵ E. Thervet,¹¹ L. Rostaing,² Y. Lebranchu.¹
¹Service de Transplantation rénale, CHRU, Tours, France; ²Service de Transplantation Rénale, CHU, Toulouse, France; ³Service de Transplantation Rénale, CHU, Reims, France; ⁴Service Transplantation Rénale, CHU, Rouen, France; ⁵Service de Transplantation Rénale, APHP, Kremlin Bicêtre, France; ⁶Service de Transplantation Rénale, CHU, Nice, France; ⁷Service de Transplantation Rénale, CHU, Rennes, France; ⁸Service de Transplantation Rénale, CHU, Limoges, France; ⁹Service de Transplantation Rénale, CHU, Brest, France; ¹⁰Service de Transplantation Rénale, CHU, Caen, France; ¹¹Service de Néphrologie, APHP, Centre Européen Georges Pompidou, Boulogne-Billancourt, France.
Introduction. The aim of the study was to determine the efficacy and safety balance of 2 different doses of tacrolimus extended-release (TacER) in kidney transplant…
2016 American Transplant Congress
Clinical Factors That Determine the Appropriateness of Early Steroid Withdrawal.
S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, D. Segev.
Johns Hopkins, Baltimore, MD.
Early steroid withdrawal (ESW) has been a popular option for recipients with low-immunological risk. However, no quantitative tools are available to assess the risk, i.e.…
2016 American Transplant Congress
Steroid Free Immunosuppression and Clinical Outcomes in Recipients of Deceased Donor Kidney Transplant with Positive Flow Cytometry Crossmatch.
O. Adebiyi, T. Taber, W. Goggins, D. Mishler, M. Yaqub, A. Sharfuddin.
Indiana University, Indianapolis.
Background: Positive flow cytometry crossmatch (FCXM) is considered a high immunologic risk for transplantation. Available studies reporting outcomes in positive FCXM kidney transplants were done…
2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.
B.-H. Shin, S. Ge, J. Choi, J. Kahwaji, A. Vo, A. Petrosyan, S. Jordan, M. Toyoda.
Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplant in HS patients. TCZ has anti-B cell and anti-inflammatory properties. We have reported its…
2016 American Transplant Congress
Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.
G. Spagnoletti, M. Salerno, V. Bianchi, N. Silvestrini, F. Apponi, J. Romagnoli.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction.Aim of this study was to evaluate the efficacy and safety of preemptive prophylaxis of CMV infection in kidney transplant recipients (KTx) receiving polyclonal antibodies…